Trial · NCT06511193
Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]
NCT06511193, Completed, AstraZeneca
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]. Trials, record NCT06511193. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06511193
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]
- NCT number
- NCT06511193
- Status
- Completed
- Enrollment
- 152 participants, actual
- Lead sponsor
- AstraZeneca
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Budenoside/Glycopyrronium/Formoterol
- First posted
- 2024-07-19
- Last updated
- 2026-06-24
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean change from baseline in the COPD Assessment Test (CAT) score | 12 weeks after treatment initiation | To estimate the change in COPD health status in patients initiating BGF after 12 weeks |
| Secondary | Demographic and clinical characteristics at baseline | At baseline | To describe the demographic and clinical characteristics of patients in the study |
| Secondary | Change from baseline in CAT score after 24 weeks of treatment | 24 weeks from treatment initiation | To estimate the change in COPD health status after 24 weeks from treatment initiation |
| Secondary | Change in patient quality of life as measured by EQ-5D-5L at 12 and 24 weeks post-treatment initiation | 12 and 24 weeks after treatment initiation | To estimate the change in patient quality of life after 12 and 24 weeks of treatment initiation |
| Secondary | Change in measures of sleep quality using CASIS (COPD and Asthma Sleep Impact Scale) at weeks 12 and 24 | 12 and 24 weeks of treatment initiation | To estimate change in sleep quality following introduction of BGF |
| Secondary | Percent responders of the CAT [MID=2] after 12 weeks treatment compared to baseline | 12 weeks treatment compared to baseline | To describe the Responder Rate based on the CAT after 12 weeks of initiating treatment with BGF |
| Secondary | The annualized rate of moderate and severe exacerbations that occurred within the previous year is collected at the baseline visit and the number of moderate and severe exacerbations occurring during the study is collected at the final visit | Baseline (12 months prior to initiating BGF) and during the follow-up period (up to 6 months)) | To describe and compare the rate of moderate and severe exacerbations |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06511193
GET https://conductscience.org/api/trials/v1/NCT06511193/registered